Drug Profile


Alternative Names: DMP 754; DMP 755; DPC 754; Lumaxis; MK 0853; XJ 754; XV 459

Latest Information Update: 28 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antiplatelets
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders; Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral arterial disorders; Thrombosis

Most Recent Events

  • 20 Sep 2002 A clinical study has been added to the adverse events section
  • 05 Apr 2001 Phase-III clinical trials for Peripheral arterial disorders in Canada (PO)
  • 05 Apr 2001 Phase-III clinical trials for Peripheral arterial disorders in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top